ophthalmologytimes2h
eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa
The company is advancing its Phase I/II trial and exploring accelerated approval pathways in the US and Europe.
ophthalmologytimes4h
The human impact of geographic atrophy: Survey examines experiences and perceptions of patients living with GA
A global survey explores the impact of geographic atrophy (GA) on quality of life, revealing similar challenges for ...